OCEANSIDE, CA--(Marketwired - May 09, 2017) - Therapeutics Solutions International, Inc., (OTC PINK: TSOI) announced today the filing of a patent for a nutraceutical product called "Cancer Metabolic Detox".

Cancer Metabolic Detox is an orally administered all natural nutraceutical product that is comprised of various herbal ingredients which seek to selectively block the cancer associated metabolic pathway that degrades the amino acid tryptophan. Specifically, the product is designed to inhibit the enzyme indolamine 2,3 deoxygenase (IDO), which is responsible for breaking down tryptophan in the vicinity of the tumor and generating by-products such as kynurenine.

It is known that immune activation is dependent on tryptophan being present in the tumor environment. The depletion of tryptophan and generation of kynurenine by tumor cells and tumor associated cells is a major cause of immune suppression in cancer¹. It is believed that by the administration of Cancer Metabolic Detox, the innate arm of the immune system has a chance to regenerate. This positions the patient for a better outcome after administration of specific immune stimulating vaccines.

"Currently, cancer treatment using immunotherapy is a costly endeavor limited to select institutions. We hope that by developing immune modulatory nutraceuticals, we can significantly decrease cost and enable access to immunotherapy," said Timothy Dixon, President and CEO of Therapeutic Solutions International.

"In previous studies, myself and collaborators, have published papers that inhibiting the IDO enzyme using gene silencing is an effective way of augmenting anti-cancer immunity²," said Dr. Thomas Ichim, Chief Executive Officer of Emvolio Inc. "We are very excited to utilize an approach that is significantly less expensive and natural to target this fundamental molecular mechanism that tumor cells use to suppress the immune system."

About Therapeutic Solutions International, Inc.
The Company's corporate website is www.therapeuticsolutionsint.com.

About Emvolio, Inc.
The Company's corporate website is www.emvolio.com.

Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

¹ Munn DH. Blocking IDO activity to enhance anti-tumor immunity. Front Biosci (Elite Ed). 2012 Jan 1;4:734-45. https://www.ncbi.nlm.nih.gov/pubmed/22201909

² Zheng et al. Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model. Int J Cancer. 2013 Feb 15;132(4):967-77 https://www.ncbi.nlm.nih.gov/pubmed/?term=22870862